TW202317120A - 表皮生長因子受體抑制劑之醫藥組合物 - Google Patents

表皮生長因子受體抑制劑之醫藥組合物 Download PDF

Info

Publication number
TW202317120A
TW202317120A TW111123289A TW111123289A TW202317120A TW 202317120 A TW202317120 A TW 202317120A TW 111123289 A TW111123289 A TW 111123289A TW 111123289 A TW111123289 A TW 111123289A TW 202317120 A TW202317120 A TW 202317120A
Authority
TW
Taiwan
Prior art keywords
weight
composition
dosage form
oral dosage
pharmaceutical composition
Prior art date
Application number
TW111123289A
Other languages
English (en)
Chinese (zh)
Inventor
凱特琳 N 金凱瑪
黛布拉 L 馬賽克
克萊爾 奧布里 孟登道
萬卡爾 賽培德 瓦澤
Original Assignee
美商纜圖藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商纜圖藥品公司 filed Critical 美商纜圖藥品公司
Publication of TW202317120A publication Critical patent/TW202317120A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111123289A 2021-06-23 2022-06-22 表皮生長因子受體抑制劑之醫藥組合物 TW202317120A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163214099P 2021-06-23 2021-06-23
US63/214,099 2021-06-23

Publications (1)

Publication Number Publication Date
TW202317120A true TW202317120A (zh) 2023-05-01

Family

ID=82608194

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111123289A TW202317120A (zh) 2021-06-23 2022-06-22 表皮生長因子受體抑制劑之醫藥組合物

Country Status (9)

Country Link
US (1) US20240293323A1 (cg-RX-API-DMAC7.html)
EP (1) EP4358942A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525206A (cg-RX-API-DMAC7.html)
CN (1) CN117835970A (cg-RX-API-DMAC7.html)
AR (1) AR126195A1 (cg-RX-API-DMAC7.html)
CA (1) CA3223889A1 (cg-RX-API-DMAC7.html)
IL (1) IL309447A (cg-RX-API-DMAC7.html)
TW (1) TW202317120A (cg-RX-API-DMAC7.html)
WO (1) WO2022271765A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523506A (ja) * 2021-06-23 2024-06-28 ブループリント メディシンズ コーポレイション 上皮成長因子受容体阻害剤の塩及び結晶形態
CN116554150B (zh) * 2022-12-30 2025-12-19 苏州浦合医药科技有限公司 第四代egfr抑制剂
WO2024249660A1 (en) * 2023-05-31 2024-12-05 Amgen Inc. Compositions comprising sotorasib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
KR102498693B1 (ko) * 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
JP2024523506A (ja) * 2021-06-23 2024-06-28 ブループリント メディシンズ コーポレイション 上皮成長因子受容体阻害剤の塩及び結晶形態

Also Published As

Publication number Publication date
WO2022271765A1 (en) 2022-12-29
EP4358942A1 (en) 2024-05-01
CN117835970A (zh) 2024-04-05
CA3223889A1 (en) 2022-12-29
JP2024525206A (ja) 2024-07-10
US20240293323A1 (en) 2024-09-05
IL309447A (en) 2024-02-01
AR126195A1 (es) 2023-09-27

Similar Documents

Publication Publication Date Title
US9962390B2 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
EP3089741B1 (en) Pharmaceutical compositions comprising azd9291
US20240293323A1 (en) Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
KR101851571B1 (ko) 탁산을 포함하는 무정형 고체 분산체, 그를 포함하는 정제 및 그를 제조하는 방법
WO2018185175A1 (en) Pharmaceutical composition comprising lenvatinib mesylate
US20230203009A1 (en) Pralsetinib pharmaceutical compositions
JP5775085B2 (ja) c−METキナーゼ阻害剤の製剤
WO2020070144A1 (en) Crystalline forms and processes of lenvatinib besylate
KR20260029301A (ko) 골수성 키놈 억제제의 고체 분산물 및 그를 포함하는 제약 조성물
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
TWI871668B (zh) 醫藥調配物
ES2963886T3 (es) Comprimidos que contienen tamsulosina y solifenacina
HK40104279A (en) Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
CN119365195A (zh) 含有匹米替比的医药组合物
US20230119355A1 (en) Pharmaceutical compositions of a kinase inhibitor
WO2007147873A1 (en) Oral pharmaceutical composition of a poorly water-soluble active substance
WO2017163268A2 (en) A sustained release pharmaceutical dosage form of divalproex
HK1228245B (en) Pharmaceutical compositions comprising azd9291